Statistics for Cost-Effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
Total visits
| views | |
|---|---|
| Cost-Effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal | 33 |
Total visits per month
| views | |
|---|---|
| November 2024 | 3 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| PharmacoEconomics Open 2023_229.pdf(legacy) | 7 |
| PharmacoEconomics Open 2023_229.pdf | 1 |
Top country views
| views | |
|---|---|
| United States | 14 |
| Australia | 6 |
| France | 4 |
| China | 3 |
| Portugal | 2 |
| Canada | 1 |
| United Kingdom | 1 |
| Latvia | 1 |
| Mongolia | 1 |